Approximately one quarter of patients who have psoriasis experience disease onset before adulthood.
New research describes patient-reported outcomes and disease burden among pediatric patients with psoriasis in the United States, United Kingdom, France, Germany, Spain, and Italy.
The condition affects 2% to 4% of individuals in western countries, researchers wrote in Acta Dermato-Venereologica, while around one quarter of patients experience disease onset prior to adulthood.
“Pediatric psoriasis (onset < 18 years) is associated with a substantial negative effect on quality of life and patients have a greater risk of developing psychosocial disorders compared with those without psoriasis,” the authors explained.
In addition, “due to the visibility of psoriatic plaques, pediatric patients with psoriasis experience social discomfort, bullying, and stigma.”
Their current analysis of a cross-sectional survey included responses from dermatologists, general practitioners or primary care practitioners, and pediatricians actively managing pediatric patients with psoriasis.
Patients aged 12 to 17 years were also invited to complete a voluntary questionnaire. A total of 324 treating physicians were included in the study, 187 of whom were dermatologists; 71, general practitioners or primary care practitioners; and 66, pediatricians.
These physicians completed 2877 patient record forms, each representing 1 pediatric patient. Those with a treatment time of less than 4 weeks for topical therapy and/or less than 12 weeks for conventional systemic and/or biologic therapy were excluded.
Of the 2379 remaining patients, the mean age was approximately 13 years and 53% were male.
“Patient-reported data were collected for 42.7% of the analyzed population, 65.5% via the patient self-completed questionnaire (PSC) and 34.5% via the carer self-completed questionnaire (CSC). For the present analysis, physician-reported data (via patient record forms) were included only for those patients with corresponding patient-reported data (ie, a matched dataset, n = 1017),” the authors wrote.
In the matched dataset, 79.8% of all patients had mild disease, 18.2% had moderate disease and 2% had severe disease.
Analyses revealed:
Data also showed that patients with mild forms of the disease had the highest level of treatment satisfaction, while greater proportions of patients with moderate or severe disease were dissatisfied with their treatment. The main reason for treatment dissatisfaction was a lack of clear skin.
The mean Children’s Dermatology Life Quality Index (CDLQI) scores were around 5 despite 80% of patients reporting mild disease, the study authors wrote, with scores substantially higher in those with more severe disease.
“The current study showed that patients frequently experienced itch, with greater severity of itching in patients with more severe psoriasis. Furthermore, itch impacted school, sleep, and physical and social activities, and itch severity correlated with CDLQI,” they added.
The subjective, physician-judged severity assessments included mark potential limitations of the study.
Overall, “management of pediatric psoriasis should consider the impact of disease on health-related QoL, patient perceptions on treatment satisfaction, and treatment goals,” researchers concluded.
Reference
Seyger MMB, Paller AS, Sticherling M, et al. Patient-reported outcomes and burden of disease in pediatric patients with psoriasis: real-world data from EU5 and US. Acta Derm Venereo. Published online April 19, 2023. doi:10.2340/actadv.v103.2544
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Margin Status Likely Not a Factor in STS Recurrence
May 10th 2024The optimal negative margin required following surgical resection and perioperative radiotherapy for extremity soft tissue sarcoma (STS) remains up for debate, with investigators of a new study using Union for International Cancer Control classification to define resection margin.
Read More
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More